Anaphylactoid

COVID-19 vaccination guidance for people with bleeding ...

Dec 22, 2020 · people with a history of allergic/anaphylactoid reactions can be found in the advisory published by each agency. 13. For patients in a clinical study, vaccination should be reported to the study investigators. Information will be updated on the WFH, EAHAD, EHC, and NHF websites as needed. Resources: COVID-19 WFH Announcements and Statements

  Anaphylactoid

Heparin-induced thrombocytopenia Guideline

Anaphylactoid reactions2. Page 4 of 12 o Rarely, patients develop acute inflammatory (e.g., fever, chills, flushing) or cardiorespiratory (e.g., hypertension, tachycardia, dyspnea, chest pain, cardiorespiratory arrest) symptoms and signs within 30 minutes following an IV heparin bolus (or subcutaneous LMWH).

  Anaphylactoid

Section 4.8 Undesirable effects - European Medicines Agency

An agency of the European Union Section 4.8: Undesirable effects Rev. 1 SmPC training presentation Note: for full information refer to the European Commission’s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group